Press Release                                              Source: Avitar, Inc.

Avitar Signs Distribution Agreement for Hydrasorb with Dukal Corporation
Tuesday December 12, 8:45 am ET

CANTON,  Mass., Dec. 12 /PRNewswire/ -- Avitar (OTC Bulletin Board: AVTI - News;
"Company")  has  signed a  distribution  agreement  with Dukal  Corporation  for
Avitar's Hydrasorb (TM) polyurethane foam wound dressing product line to replace
the Company's existing  distributor.  The agreement covers the United States and
will be effective January 1, 2007.

Hydrasorb,  which uses Avitar's proprietary polyurethane technology, is a highly
absorbent topical dressing for moderate to heavy exuding wounds. These dressings
have a unique  construction  that  provides a moist wound  healing  environment,
which  promotes  skin growth and  closure.  Dukal  Corporation  will  distribute
Hydrasorb  to acute care  hospitals  as well as  subacute,  long-term  and other
health care facilities throughout the U.S.


"Dukal is a  recognized  industry  leader and will help us to further  our wound
care product line more successfully  through its already  established network of
independent distributors," said Peter P. Phildius,  Chairman and Chief Executive
Officer of Avitar.  "We are pleased  with this  agreement  and are  enthusiastic
about working with Dukal to expand Hydrasorb's share of the specialty wound care
market."


"Dukal is delighted with this agreement," said Gerry LoDuca,  President of Dukal
Corporation.  "Hydrasorb is a well-established product that fits nicely with our
long-term  growth  strategy.  We look  forward to working with Avitar to further
develop the application for its Hydrasorb  technology in this growing segment of
the wound care market."


About Dukal Corporation


Dukal Corporation,  headquartered in Hauppauge,  New York, has been dedicated to
manufacturing  products since its inception in 1991. Recognizing a need to offer
the  consumer  a premium  product at  affordable  pricing,  Dukal  offers a wide
variety  of wound care and  specialty  patient  care  products  for all  medical
markets. For more information, see Dukal's website at www.dukal.com


About Avitar, Inc.


Avitar,  Inc.  develops,  manufactures  and markets  innovative and  proprietary
products.  Its field includes the oral fluid diagnostic  market, the disease and
clinical testing market,  and customized  polyurethane  applications used in the
wound dressing  industry.  Avitar  manufactures  ORALscreen(R) the world's first
non-invasive,  rapid,  on-site,  fluid-based  oral  screening  test  for  drugs-
of-abuse, as well as HYDRASORB(R), an absorbent topical dressing for moderate to
heavy  exudating  wounds.  Avitar is also developing  diagnostic  strategies for
disease and clinical testing in the estimated $25 billion  in-vitro  diagnostics
market. Conditions targeted include influenza, diabetes, and pregnancy. For more
information, visit Avitar's Web site at www.avitarinc.com.


Forward Looking Statements


This release contains  forward looking  statements that are subject to risks and
uncertainties  including the development and marketing of new  applications  and
other risks that are detailed  from time to time in the  Company's  filings with
the Securities and Exchange Commission. In view of such risks and uncertainties,
the Company's actual results could differ  materially from those  anticipated in
such forward looking statements.